Parkinson’s Disease (PD) is becoming increasingly prevalent in our ageing population and is the most common neurodegenerative movement disorder, affecting 1–2% of people aged over 65, with an estimated > 6.1 million people affected worldwide1.There has been a wealth of research into genetic and proteomic changes affected by PD2–5, however it is becoming more and more apparent that dysregulated lipid pathways also play a role in the aetiology of the disease6–9. Here, PAF1 is linked to Parkinson disease.